Speaks for itself,
ISI noted that Momenta's patent filings indicate that the remaining 5 products may include biosimilars for Rituxan, Prolia/Xgeva, Vectibix, Xolair and Campath.
"Rituximab, sold under the brand name Rituxan among others, is a medication used to treat certain autoimmune diseases and types of cancer.[2] It is used for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, idiopathic thrombocytopenic purpura, pemphigus vulgaris and myasthenia gravis.[2][3] It is given by slow injection into a vein.”
"Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody[1] for the treatment of osteoporosis,[1] treatment-induced bone loss, metastases to bone,[1] and giant cell tumor of bone.[2].”
"Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).
Panitumumab is manufactured by Amgen and marketed as Vectibix. It was originally developed by Abgenix Inc.”
"Xolair is an injectable medicine for patients 12 years of age and older with moderate to severe persistent allergic asthma whose asthma symptoms are not controlled by asthma medicines called inhaled corticosteroids.”
"Alemtuzumab is a drug used in the treatment of chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL) and T-cell lymphoma under the trade names Campath, MabCampath and Campath-1H, and in the treatment of multiple sclerosis as Lemtrada. It is also used in some conditioning regimens for bone marrow transplantation, kidney transplantation and islet cell transplantation.
and,
"We are delighted to announce this collaboration with Momenta, who are leaders in the Fc biology space,” said Paul Perreault, CEO and Managing Director, CSL. “M230 is a very exciting prospect and offers CSL the potential to further grow and expand our long-term global leadership in helping those patients with autoimmune diseases that are treated with immunoglobulins.”
Under the terms of the agreement, Momenta will grant CSL an exclusive, worldwide license to Momenta’s intellectual property relating to M230. Momenta will receive a $50 million upfront license fee payment from CSL and will also be eligible for up to $550 million in contingent clinical, regulatory and commercialization milestone payments. Momenta has the option to elect a cost and profit sharing arrangement, for which Momenta would fund a proportion of global development and commercialization costs in exchange for a share of U.S. profits, and milestones and royalties outside the United States. Momenta has the option to enter into an agreement to co-promote M230 and any other collaboration product in the U.S.”
MNTA has opted in for the 50% sharing.
Found this=
"Preclinical
Autoimmune disorders; Epidermolysis bullosa; Rheumatoid arthritis
Most Recent Events
05 Jan 2017CSL enters into agreement to in-license M 230
17 Nov 2016Preclinical trials in Epidermolysis bullosa in USA (Parenteral)
17 Nov 2016Preclinical trials in Rheumatoid arthritis in USA (Parenteral) "
This,
"At the end of November 2016, the firm.MNTA, reported positive topline data from a confirmatory Phase III study evaluating M923, a biosimilar of Humira® (adalimumab) We own this one 100%."
Boing X 2
